Brind.

The Health Sciences Authority (HSA) approved Beyfortus from both Sanofi and AstraZeneca for use in infants.

2 reports, 1 independent Updated Aug 19

Gone quiet

Reports: 2
Developments: 3
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The Health Sciences Authority (HSA) approved Beyfortus from both Sanofi and AstraZeneca for use in infants.

Who's involved

What this event is mainly about

Sanofi AstraZeneca Health Sciences Authority

How it developed

Newest first. Tap a step to see who reported it.

Jun 8Sanofi and AstraZeneca announced a partnership regarding the drug Beyfortus.Sub-event
Aug 19HSA granted infant approval for Beyfortus from Sanofi and AstraZeneca.1 source
- PR Newswire
Jul 22Beyfortus showed 87% reduction in RSV incidence in clinical findings.1 source
- PR Newswire

Keep exploring

The entities involved

Sanofi
company in Milan, Italy

Nothing else this week.
AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
- Pharmaceutical companies are adopting AI for clinical data gathering, product promotion, and prototyping.Sat 18:52
Health Sciences Authority
Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 19PR NewswireBeyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven h
Jul 22PR NewswireBEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study 87% reduction in cases of respiratory syncytial virus (RSV) disease across all